Curcumin, the active principle of turmeric (Curcuma longa), ameliorates diabetic nephropathy in rats

Clinical and Experimental Pharmacology and Physiology

Volumn 33, Issue 10, 2006, Pages 940-945

  Sharma, Sameer ^a   Kulkarni, Shrinivas K ^a   Chopra, Kanwaljit ^a  

^a PANJAB UNIVERSITY   (India)

Author keywords

Curcumin; Diabetic nephropathy; Lipid peroxidation; Oxidative stress

Indexed keywords

ALBUMIN; CATALASE; CREATININE; CURCUMIN; ENZYME; GLUCOSE; GLUTATHIONE; MALONALDEHYDE; STREPTOZOCIN; SUPEROXIDE DISMUTASE; UREA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; ARTICLE; CONTROLLED STUDY; CREATININE URINE LEVEL; CURCUMA LONGA; DIABETIC NEPHROPATHY; DRUG EFFECT; ENZYME ACTIVITY; GLUCOSE BLOOD LEVEL; KIDNEY DISEASE; KIDNEY FUNCTION; LIPID PEROXIDATION; MALE; NONHUMAN; OXIDATIVE STRESS; POLYURIA; PROTEINURIA; RAT; STREPTOZOCIN DIABETES; UREA NITROGEN BLOOD LEVEL; URIC ACID URINE LEVEL; WEIGHT REDUCTION;

ANIMALS; BLOOD GLUCOSE; BLOOD PRESSURE; BODY WEIGHT; CATALASE; CURCUMA; CURCUMIN; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC NEPHROPATHIES; DRUG EVALUATION, PRECLINICAL; GLUTATHIONE; KIDNEY; MALONDIALDEHYDE; OXIDATIVE STRESS; PLANT EXTRACTS; RATS; RATS, SPRAGUE-DAWLEY; SUPEROXIDE DISMUTASE; SURVIVAL RATE;

EID: 33748891024     PISSN: 03051870     EISSN: 14401681     Source Type: Journal    
DOI: 10.1111/j.1440-1681.2006.04468.x     Document Type: Article

References (27)

1. Ha H, Kim KH. Pathogenesis of diabetic nephropathy: The role of oxidative stress and protein kinase C. Diabetes Res. Clin. Pract. 1999; 45: 147-51.
2. Paolisso G, Amore DA, Galzerano D. Daily vitamin E supplements improve metabolic control but not insulin secretion in elderly type II diabetic patients. Diabetes Care 1993; 16: 433-7.
3. Ruiz C, Alegria A, Barbera R, Farre R, Lagarda MJ. Lipid peroxidation and antioxidant enzyme activities in patients with type-I diabetes mellitus. Scand. J. Clin. Lab. Invest. 1994; 59: 99-105.
4. Cooper ME. Interaction of metabolic and homodynamic factors in mediating experimental diabetic nephropathy. Diabetologia 2001; 44: 1957-72.
5. Literat A, Su F, Norwicki M et al. Regulation of pro-inflammatory cytokine expression by curcumin in hyaline membrane disease (HMD). Life Sci. 2001; 70: 253-67.
6. Iqbal M, Sharma SD, Okazaki Y, Fujisawa M, Okada S. Dietary supplementation of cucumin enhances antioxidant and phase-II metabolising enzymes in ddY male mice: Possible role in protection against chemical carcinogenesis and toxicity. Pharmacol. Toxicol. 2003; 92: 33-8.
7. Indian National Science Academy. Guidelines for Care and Use of Animals in Scientific Research. INSA, New Delhi. 1992.
8. Murali B, Goyal RK. Effect of chronic treatment with losartan on streptozotocin induced diabetic nephropathy. Clin. Exp. Hypertens. 2001; 23: 513-20.
9. Schmidt FH. Methodon der har-und blutzuckerbestrimmung II. In: Pfeiffer EF (ed.). Handbuch Des Diabetes Mellitus, vol. 2. JF Lehmanns Verlag, Munich. 1971; 938.
10. Anjaneyulu M, Ramarao P. Studies on gastrointestinal tract functional changes in diabetic animals. Methods Find. Exp. Clin. Pharmacol. 2002; 2: 71-5.
11. Ferrari AU, Daffonchio A, Albergati F, Bertoli P, Mancia G. Intra-arterial pressure alterations during tail-cuff blood pressure measurements in normotensive and hypertensive rats. J. Hypertens. 1990; 8: 909-11.
12. Wills ED. Mechanism of lipid peroxide formation in animal tissues. Biochem. J. 1996; 99: 667-76.
13. Ellman GL. Tissue sulfhydryl group. Arch. Bochem. Biophys. 1959; 82: 70-7.
14. Kono Y. Generation of superoxide radical during autoxidation of hydroxylamine and an assay for superoxide dismutase. Arch. Biochem. Biophys. 1978; 186: 189-95.
15. Luck H. Catalase. In: Bergmeyer HU (ed.). Methods of Enzymatic Analysis. Academic Press, New York. 1971; 885-93.
16. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the Folin-phenol reagent. J. Biol. Chem. 1951; 193: 265-75.
17. Sugimoto K, Tsuruoka S, Fujimura A. Effect of enalapril on diabetic nephropathy in OLETF rats: The role of an anti-oxidative action in its protective properties. Clin. Exp. Pharmacol. Physiol. 2001; 28: 829-30.
18. Murali B, Goyal RK. Effect of chronic treatment with losartan on streptozotocin induced diabetic nephropathy. Clin. Exp. Hypertens. 2001; 23: 513-20.
19. Craven PA, Melhem MF, DeRubertis FR. Thromboxane in the pathogenesis of glomerular injury in diabetes. Kidney Int. 1992; 42: 937-46.
20. Tirkey N, Kaur G, Vij G, Chopra K. Curcumin, a diferuloylmethane, attenuates cyclosporine-induced renal dysfunction and oxidative stress in rat kidneys. BMC Pharmacol. 2005; 5: 15-24.
21. Ghoneim AI, Abdel-Naim AB, Khalifa AE, El-Denshary ES. Protective effects of curcumin against ischaemia/reperfusion insult in rat forebrain. Pharmacol. Res. 2002; 46: 273-9.
22. Ishihara M, Sakagami H. Re-evaluation of cytotoxicity and iron chelation activity of three beta-diketones by semiempirical molecular orbital method. In Vivo 2005; 19: 119-23.
23. Lehmann R, Schleicher ED. Molecular mechanism of diabetic nephropathy. Clin. Chim. Acta 2000; 297: 135-44.
24. Wilmer WA, Dixon CL, Hebert C. Chronic exposure of human mesangial cell to high glucose environments activates the p38 MAPK pathway. Kidney Int. 2001; 60: 858-71.
25. Gaedeke J, Noble NA, Border WA. Curcumin blocks multiple sites of the TGF-beta signalling cascade in renal cells. Kidney Int. 2004; 66: 112-20.
26. Punithavathi D, Venkatesan N, Babu M. Protective effects of curcumin against amiodarone-induced pulmonary fibrosis in rats. Br. J. Pharmacol. 2003; 139: 1342-50.
27. Jeong WS, Kim IW, Hu R, Kong AN. Modulatory properties of various natural chemopreventive agents on the activation of NF-kappa B signalling pathway. Pharm. Res. 2004; 2: 661-70.